|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1016 W Jackson Blvd |
Address2 | #1073 |
| City | Chicago |
State | IL |
Zip Code | 60607 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 400348610-12
|
||||||||
|
6. House ID# 403510000
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Paul Melmeyer |
Date | 2/27/2025 2:07:11 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Prepared efforts for reauthorization of the Newborn Screening Saves Lives Reauthorization Act
Encouraged action on telehealth legislation to the Energy and Commerce Committee
Supported H.R. 7623, the Telehealth Modernization Act of 2024
Supported H.R. 7858, Telehealth Enhancement for Mental Health Act and the Telehealth Modernization Act:
Supported the ALS Better Care Act
Advocated for the protection of the Medicaid program to the White House and Congress
Supported H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act
Supported H.R. 7384, Creating Hope Reauthorization Act of 2024
Supported the amended Give Kids a Chance Act
Supported the MINI Act
Supported the NIH Clinical Trial Diversity Act
Supported H.R. 4758, Accelerating Kids Access to Care Act
Supported the Access to Genetic Counseling Services Act
Advocated for provisions addressing problems within the pharmacy benefit manager industry
Supported the introduction of legislation that amends the anti-kickback statute to allow companies to cover the costs of traveling to obtain therapies
Supported robust funding for NCATS
Supported robust funding for NIAMS
Prepared for the reauthorization of the ACT for ALS
Joined coalition Comments to Congressional Leadership on Potential Changes to Medicaid (12.19.24)
Joined an Amicus Brief in American Association of Ancillary Benefits v. Becerra (12.18.24)
Joined Coalition Comments to Centers for Medicare and Medicaid Services on Long-Term Care (LTC) Pharmacies (12.17.24)
Joined Coalition Comments to Centers for Medicare and Medicaid Services on Federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) Program (12.16.24)
Joined Coalition Comments to Congressional Leadership on Partnership to Protect Coverage Healthcare Priorities (12.10.24)
Joined Coalition Comments to House Budget Committee and Senate Budget Committee Leadership on Protection of and Potential Cuts to Medicaid (12.10.24)
Joined Amicus Briefs Filed in Response to Challenges to Section 1557 of the Affordable Care Act (ACA) Final Rule from U.S. Department of Health and Human Services: Texas v. Becerra (12.4.24) and Tennessee v. Becerra (11.26.24)
Joined Coalition Comments to Congressional Leadership on Diagnostic Medical Equipment (DME) Access (12.2.24)
Joined Coalition Comments to HHS on Notice of Benefit and Payment Parameters for 2026 (11.12.24)
Joined Coalition Comments in Response to Proposed Data Collection on Proprietary Guidelines and Medicare Advantage Plan Audit Protocol (11.12.24)
Joined Coalition Comments to Support S.5070, the Ensuring Access to Medicaid Buy-In Programs Act (11.12.24)
Joined Coalition Comments on Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2026; Basic Health Program (11.12.24)
Joined Coalition Comments on Access to Assistive Technology, Auxiliary Aids, Services, and Accommodations (11.6.24)
Joined Coalition Comments to UnitedHealthcare on Changes to Prior Authorization Policies for Outpatient Rehabilitation Therapy Services (10.22.24)
Joined Coalition Comments to Centers for Medicare & Medicaid Services (CMS) on Service Level Data Collection for Medicare Advantage Plans (10.8.24)
Supported efforts to reform the Inflation Reduction Acts provisions on Medicare negotiation for orphan drugs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
|
Shannon |
Wood |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AVI
16. Specific lobbying issues
Joined Coalition Comments to President Biden Urging Finalization of Ensuring Safe Accommodations for Air Travelers with Disabilities Using Wheelchairs Rule (11.26.2024)
Discussed the implementation of the FAA reauthorization with congressional partners
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Federal Aviation Administration (FAA), Transportation - Dept of (DOT)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Shannon |
Wood |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Supported enhanced funding for NCATS, NIAMS, and the entire NIH
Supported robust appropriations for the newborn screening program.
Joined Coalition Comments to House Budget Committee and Senate Budget Committee Leadership on Protection of and Potential Cuts to Medicaid (12.10.24)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Defense - Dept of (DOD), Education - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
|
Shannon |
Wood |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Prepared efforts for reauthorization of the Newborn Screening Saves Lives Reauthorization Act
Supported H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act
Supported H.R. 7384, Creating Hope Reauthorization Act of 2024
Supported the amended Give Kids a Chance Act
Supported the NIH Clinical Trial Diversity Act
Supported robust funding for NCATS
Prepared for the reauthorization of the ACT for ALS
Supported efforts to reform the Inflation Reduction Acts provisions on Medicare negotiation for orphan drugs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Health Resources & Services Administration (HRSA), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Supported the ALS Better Care Act
Advocated for the protection of the Medicaid program to the White House and Congress
Supported the MINI Act
Supported H.R. 4758, Accelerating Kids Access to Care Act
Supported the introduction of legislation that increases access to genetic testing and genetic counselors
Encouraged action on telehealth legislation to the Energy and Commerce Committee
Supported H.R. 7623, the Telehealth Modernization Act of 2024
Supported H.R. 7858, Telehealth Enhancement for Mental Health Act and the Telehealth Modernization Act:
Supported the Access to Genetic Counseling Services Act
Joined coalition Comments to Congressional Leadership on Potential Changes to Medicaid (12.19.24)
Joined Coalition Comments to Centers for Medicare and Medicaid Services on Long-Term Care (LTC) Pharmacies (12.17.24)
Joined Coalition Comments to Centers for Medicare and Medicaid Services on Federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) Program (12.16.24)
Joined Coalition Comments to Congressional Leadership on Partnership to Protect Coverage Healthcare Priorities (12.10.24)
Joined Coalition Comments to House Budget Committee and Senate Budget Committee Leadership on Protection of and Potential Cuts to Medicaid (12.10.24)
Joined Coalition Comments to Congressional Leadership on Diagnostic Medical Equipment (DME) Access (12.2.24)
Joined Coalition Comments in Response to Proposed Data Collection on Proprietary Guidelines and Medicare Advantage Plan Audit Protocol (11.12.24)
Joined Coalition Comments to Support S.5070, the Ensuring Access to Medicaid Buy-In Programs Act (11.12.24)
Joined Coalition Comments to Centers for Medicare & Medicaid Services (CMS) on Service Level Data Collection for Medicare Advantage Plans (10.8.24)
Supported efforts to reform the Inflation Reduction Acts provisions on Medicare negotiation for orphan drugs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
|
Shannon |
Wood |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Supported H.R. 7623, the Telehealth Modernization Act of 2024
Supported H.R. 7858, Telehealth Enhancement for Mental Health Act and the Telehealth Modernization Act:
Supported the ALS Better Care Act
Advocated for the protection of the Medicaid program to the White House and Congress
Supported H.R. 4758, Accelerating Kids Access to Care Act
Supported the introduction of legislation that increases access to genetic testing and genetic counselors
Supported the Access to Genetic Counseling Services Act
Advocated for provisions addressing problems within the pharmacy benefit manager industry
Joined coalition Comments to Congressional Leadership on Potential Changes to Medicaid (12.19.24)
Joined an Amicus Brief in American Association of Ancillary Benefits v. Becerra (12.18.24)
Joined Coalition Comments to Centers for Medicare and Medicaid Services on Long-Term Care (LTC) Pharmacies (12.17.24)
Joined Coalition Comments to Centers for Medicare and Medicaid Services on Federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) Program (12.16.24)
Joined Coalition Comments to Congressional Leadership on Partnership to Protect Coverage Healthcare Priorities (12.10.24)
Joined Coalition Comments to House Budget Committee and Senate Budget Committee Leadership on Protection of and Potential Cuts to Medicaid (12.10.24)
Joined Amicus Briefs Filed in Response to Challenges to Section 1557 of the Affordable Care Act (ACA) Final Rule from U.S. Department of Health and Human Services: Texas v. Becerra (12.4.24) and Tennessee v. Becerra (11.26.24)
Joined Coalition Comments to Congressional Leadership on Diagnostic Medical Equipment (DME) Access (12.2.24)
Joined Coalition Comments to HHS on Notice of Benefit and Payment Parameters for 2026 (11.12.24)
Joined Coalition Comments in Response to Proposed Data Collection on Proprietary Guidelines and Medicare Advantage Plan Audit Protocol (11.12.24)
Joined Coalition Comments to Support S.5070, the Ensuring Access to Medicaid Buy-In Programs Act (11.12.24)
Joined Coalition Comments on Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2026; Basic Health Program (11.12.24)
Joined Coalition Comments on Access to Assistive Technology, Auxiliary Aids, Services, and Accommodations (11.6.24)
Joined Coalition Comments to UnitedHealthcare on Changes to Prior Authorization Policies for Outpatient Rehabilitation Therapy Services (10.22.24)
Joined Coalition Comments to Centers for Medicare & Medicaid Services (CMS) on Service Level Data Collection for Medicare Advantage Plans (10.8.24)
Supported efforts to reform the Inflation Reduction Acts provisions on Medicare negotiation for orphan drugs
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Justice - Dept of (DOJ)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
|
Shannon |
Wood |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Encouraged action on telehealth legislation to the Energy and Commerce Committee
Supported H.R. 7623, the Telehealth Modernization Act of 2024
Supported H.R. 7858, Telehealth Enhancement for Mental Health Act and the Telehealth Modernization Act:
Supported H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act
Supported H.R. 7384, Creating Hope Reauthorization Act of 2024
Supported the amended Give Kids a Chance Act
Supported the introduction of legislation that increases access to genetic testing and genetic counselors
Advocated for provisions addressing problems within the pharmacy benefit manager industry
Supported the introduction of legislation that amends the anti-kickback statute to allow companies to cover the costs of traveling to obtain therapies
Prepared for the reauthorization of the ACT for ALS
Joined an Amicus Brief in American Association of Ancillary Benefits v. Becerra (12.18.24)
Joined Coalition Comments to Centers for Medicare and Medicaid Services on Long-Term Care (LTC) Pharmacies (12.17.24)
Joined Coalition Comments to Centers for Medicare and Medicaid Services on Federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) Program (12.16.24)
Joined Coalition Comments to Congressional Leadership on Partnership to Protect Coverage Healthcare Priorities (12.10.24)
Joined Coalition Comments to HHS on Notice of Benefit and Payment Parameters for 2026 (11.12.24)
Supported efforts to reform the Inflation Reduction Acts provisions on Medicare negotiation for orphan drugs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
|
Shannon |
Wood |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRA
16. Specific lobbying issues
Joined Coalition Comments to President Biden Urging Finalization of Ensuring Safe Accommodations for Air Travelers with Disabilities Using Wheelchairs Rule (11.26.2024)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, Federal Aviation Administration (FAA), U.S. HOUSE OF REPRESENTATIVES, Transportation - Dept of (DOT)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Shannon |
Wood |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code EDU
16. Specific lobbying issues
Supported the RISE Act
Supported the Full Funding is the Right IDEA Act
Joined Coalition Comments on Access to Assistive Technology, Auxiliary Aids, Services, and Accommodations & Use of Assistive Technology in PreK-16 Schools (11.13.24)
17. House(s) of Congress and Federal agencies Check if None
Education - Dept of, U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Shannon |
Wood |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code RET
16. Specific lobbying issues
Supported the SSI Savings Penalty Elimination Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Social Security Administration (SSA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shannon |
Wood |
|
|
|
Paul |
Melmeyer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Supported the ENABLE Act, legislation to better amplify the importance of ABLE accounts
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shannon |
Wood |
|
|
|
Paul |
Melmeyer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DIS
16. Specific lobbying issues
Filed Comments to Federal Emergency Management Agency (FEMA) on Proposed Rule to Update FEMA Public Assistance Regulations (10.18.24)
17. House(s) of Congress and Federal agencies Check if None
Federal Emergency Management Agency (FEMA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Shannon |
Wood |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
Joined Amici Curiae Brief to U.S. District Court in Deferred Action for Childhood Arrivals Case, Kansas et al. v. U.S. (10.2.24)
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Shannon |
Wood |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |